Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses.
OBJECTIVE
To investigate liver fibrosis, TGF-?1 levels and curative effects on hepatocellular carcinoma (HCC) with small and conventional dose perfusion chemotherapy by transcatheter arterial chemo embolization (TACE).


METHODS
Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super- selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups.


RESULTS
With conventional doses, four indices of liver fibrosis focusing on hyaluronate acide (HA), human procollagen type-III (hPC-III), collagen type-IV (IV-C) and transforming growth factor-βl (TGF-β1) were obviously increased postoperative compared with preoperative (P<0.01); in contrast, with small doses there were no significant differences except for TGF-β1. Five year survival demonstrated no significant differences between the two groups (P>0.05).


CONCLUSIONS
To hepatocellular carcinoma patients treated by TACE, reducing doses of chemotherapy drugs can reduce progress of liver fibrosis, without impacting on five year survival.
Department of Radiology, Renhe Hospital, Yichang, China. lihongmed@yeah.net
Hong
H
Li
Yaohong
Y
Hu
Na
N
Li
Yan
Y
Zhou
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D016009:Chi-Square Distribution; D024061:Collagen Type III / Q000097:blood; D024141:Collagen Type IV / Q000097:blood; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D007459:Iodized Oil / Q000008:administration & dosage; D053208:Kaplan-Meier Estimate; D007797:Laminin / Q000097:blood; D008103:Liver Cirrhosis / Q000097:blood* / Q000139:chemically induced / Q000517:prevention & control; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D053773:Transforming Growth Factor beta1 / Q000097:blood; D016896:Treatment Outcome
D024061:Collagen Type III; D024141:Collagen Type IV; D007797:Laminin; D053773:Transforming Growth Factor beta1; D015251:Epirubicin; D016685:Mitomycin; D007459:Iodized Oil; D006820:Hyaluronic Acid; D005472:Fluorouracil